Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kristin Rojas

Surgical Oncology Miami, FL Medical Doctor

NPI 1396185997 CMS profile 17942

1475 Nw 12Th Ave, Miami, FL 33136

Open in the dashboard

General payments

$56,967

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristin Rojas of Miami, FL is reported in the CMS Open Payments database as having received $56,967 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,796 19
2024 General $4,877 13
2023 General $1,481 7
2022 General $13,482 15
2021 General $11,330 10
2020 General $18,526 12
2019 General $3,475 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristin Rojas
  • Surgical Oncology median
  • Middle half of Surgical Oncology
  • National median

In program year 2025, general payments to Kristin Rojas were reported at $3,796. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.

Show as a table
Year Kristin Rojas Surgical Oncology median Middle half National median
2019 $3,475 $236 $86–$1,064 $163
2020 $18,526 $130 $47–$648 $114
2021 $11,330 $160 $53–$943 $132
2022 $13,482 $199 $76–$782 $149
2023 $1,481 $246 $95–$854 $160
2024 $4,877 $271 $106–$1,123 $164
2025 $3,796 $288 $118–$1,346 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Roche Molecular Systems, Inc. $24,239 18 payments
  2. Pacira Pharmaceuticals Incorporated $20,687 21 payments
  3. TerSera Therapeutics LLC $5,652 13 payments
  4. Merck Sharp & Dohme Corporation $3,043 7 payments
  5. Novartis Pharmaceuticals Corporation $1,875 1 payment
  6. AxoGen $500 1 payment
  7. Endomagnetics Ltd $240 3 payments
  8. Davol Inc. $168 1 payment
  9. Hologic, LLC $147 1 payment
  10. Daiichi Sankyo Inc. $115 5 payments
  11. Other $301 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $45,508 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,000 2 payments
  3. Travel and Lodging $4,377 15 payments
  4. Food and Beverage $2,083 36 payments
Products named General payments · program years 2019–2025
  1. DIAGNOSTICS INFORMATION SYSTEMS $14,400 7 payments
  2. Exparel Pain Management $12,392 12 payments
  3. EXPAREL Pain Management $7,475 8 payments
  4. Zoladex $5,652 13 payments
  5. Iovera $4,688 6 payments
  6. Zilretta $3,868 5 payments
  7. KISQALI $1,875 1 payment
  8. AXOGUARD Neurology $500 1 payment
  9. AXOGUARD Neurology $500 1 payment
  10. AXOGUARD HA+ NERVE PROTECTOR $500 1 payment
  11. Other $2,314 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$19,164

Medicare's payments for the services billed

Medicare patients

61

Average age 71

Services billed

124

61 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 62%
Arthritis 51%
Osteoporosis 26%
Depression 25%
Diabetes 21%
Ischemic heart disease 21%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoladex
  • TerSera Therapeutics LLC $2,873
$2,873 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $1,875
$1,875 — —
ENHERTU
  • Daiichi Sankyo Inc. $44
$44 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $19
$19 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgical Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record